ArticleIn vivo (Athens, Greece)
Temporal Trends in Antineoplastic Agent-associated Interstitial Lung Disease Involving Immune Checkpoint Inhibitors in the JADER Database.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimCancer pharmacotherapy has advanced substantially with the introduction of novel agents such as immune checkpoint inhibitors (ICIs). However, managing drug-induced interstitial lung disease (DIILD) associated with these agents remains a major clinical challenge in maintaining treatment. Detailed investigations into recent changes in DIILD reporting and specific drug categories contributing to these changes remain limited. Therefore, we aimed to identify factors contributing to recent changes in DIILD reports by analyzing temporal trends in antineoplastic agent-associated DIILD using the Japanese Adverse Drug Event Report database. MATERIALS AND
methodsWe analyzed the database reports from 2004 to 2024. The reporting odds ratio (ROR) and Weibull model were used to evaluate safety signals and the time to onset of ICI-associated DIILD, respectively.
resultsThe mean rate of antineoplastic agent-associated DIILD among total adverse event reports was significantly higher in the most recent period (2016-2024) than in the earlier period (2004-2015) (25.9%
conclusionThe recent increase in antineoplastic agent-associated DIILD may primarily be driven by the expanding use of ICIs, particularly ICI in combination with chemotherapy. Because DIILD tends to occur in the early phase of treatment, strict monitoring is warranted during the initial therapy period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.